Boomi Announces New AI Agents Available on the Boomi Enterprise Platform, Enabling Unmatched Speed for Innovation
Boomi™, the intelligent integration and automation leader, today announced that the six inaugural Boomi AI Agents recently unveiled at the company’s Boomi World event will be available in the Boomi Enterprise Platform as part of existing customer licenses, enabling customers to fully harness AI-powered capabilities for unparalleled innovation. These agents include:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240611275117/en/
Boomi Announces New AI Agents Available on the Boomi Enterprise Platform, Enabling Unmatched Speed for Innovation (Graphic: Business Wire)
- Boomi Answers: Save time spent searching through user community discussions and articles. Simply ask questions about Boomi and get the most useful answer from over 240K community users.
- Boomi DataDetective: Stay on top of data privacy, protect sensitive information with AI-powered data classification, and track where data is being moved.
- Boomi DesignGen: Ask GenAI to design integration processes based on 200M+ common patterns and best practices.
- Boomi GPT: Describe integration and automation needs using natural language and have conversations with the Boomi Enterprise Platform to get more meaningful results, faster.
- Boomi Pathfinder: Provide patented suggestions on the next best steps to take when building integration processes.
- Boomi Scribe: Skip manually writing documentation about existing and AI-generated integration processes, and let GenAI handle the busywork of detailing process descriptions and business use cases.
To accelerate innovation, Boomi recently introduced the Boomi AI Agent Framework, a set of integration and no-code development capabilities that enable business and IT users to run AI agents built by Boomi or Boomi partners, and to build and run their own AI agents to solve pressing integration and automation requirements.
“AI agents are revolutionizing industries by automating repetitive tasks, analyzing vast datasets, and offering personalized customer service,” said Steve Lucas, CEO at Boomi. “Data is the lifeblood of AI, especially with pre-trained transformers and LLM's. Boomi delivers that data, and the Boomi AI Agents improve efficiency, accuracy, and scalability for organizations by operating around the clock with high precision, enhancing decision-making, supporting human workers, and driving innovation. These capabilities lead to increased productivity and cost savings, making them invaluable assets for organizations to maintain a competitive edge."
AI agents are sophisticated software entities designed with a specific scope and personality, enabling them to function within predefined parameters and exhibit particular behaviors. Operating autonomously, they can make decisions using advanced AI-based reasoning algorithms, and can independently take actions to achieve their objectives. AI agents can function with or without human intervention. Additionally, AI agents can either work independently or collaborate with other AI agents, depending on the requirements of the task at hand. This flexibility and autonomy make AI agents highly versatile and capable of performing a wide range of functions across various applications, improving decision-making processes with data-driven insights, and powering innovation by enabling new applications and services.
The Boomi AI Agent Framework includes three types of agents running on the Boomi Enterprise Platform:
Boomi AI Agents
Boomi AI Agents provide AI-powered capabilities within the platform. These capabilities can be utilized through the Boomi GPT conversational user interface (CUI), via specialized GUI, in the process canvas, or via API.
Partner AI Agents
Partner AI agents are pluggable components that allow Boomi Enterprise Platform users to install and use best-of-breed AI functions from Boomi’s network of partners. These agents can be utilized in the same way as Boomi AI Agents, and allow rich capabilities to be incorporated from across the digital ecosystem. An example is the recently announced Boomi FinTalk powered by Vianai agent that allows business users to get detailed responses on financial information via Boomi GPT.
User-created AI Agents
User-created AI agents are developed using the Boomi Enterprise Platform, which provides all the necessary building blocks. Boomi’s connectivity and orchestration capabilities enable users to interact with selected models via API, access proprietary data sources, and automate actions through various applications. The Boomi platform’s process canvas allows the creation of sophisticated workflows to retrieve, combine, filter, and contextualize data, facilitating model prompting and techniques like RAG and fine-tuning. Boomi DataHub serves as an access point and repository for the agents’ knowledge base, while Boomi Flow and Boomi API Management offer human or machine interfaces to package these components into standalone AI agents.
Boomi AI Agents will be available with the July 2024 release of the Boomi Enterprise Platform. More information can be found here.
Additional Resources
- Read up on the latest blog posts from the Boomi leadership team
- Explore the Boomiverse Community
- Follow Boomi on X (Twitter), LinkedIn, Facebook, and YouTube
About Boomi
Boomi powers the future of business with intelligent integration and automation. As a category-leading, global software as a service (SaaS) company, Boomi celebrates more than 20,000 global customers and a worldwide network of 800 partners. Organizations turn to Boomi’s award-winning platform to connect their applications, data, and people to accelerate digital transformation. For more information, visit boomi.com.
© 2024 Boomi, LP. Boomi, the ‘B’ logo, and Boomiverse are trademarks of Boomi, LP or its subsidiaries or affiliates. All rights reserved. Other names or marks may be the trademarks of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240611275117/en/
Contacts
Media
Kristen Walker
Global Corporate Communications
kristenwalker@boomi.com
+1-415-613-8320
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK ® , a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 09:03:00 EEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least one non-class I mutation, meaning more patients would be eligible for a medicine that gets them closer to normal levels of sweat chloride,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. “CFTR modulators have already revolutionized the way we treat CF and I am encoura
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 08:02:00 EEST | Press release
Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization and further development of pridopidine in Europe and other select markets. Pridopidine is a potent and highly selective, orally administered sigma-1 receptor (S1R) agonist designed to regulate key neuroprotective mechanisms often impaired in neurodegenerative diseases such as HD and ALS. Under the terms of the agreement, Prilenia will receive an upfront payment of approximately €80 million plus up to €45 million in near-term development, regulatory, and commercial milestones. The total deal is valued at up to approximately €500 million in upfront and total milestone payments. In addition, Prilenia will receive tiered double-digit royalties on
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 08:00:00 EEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 12:36:00 EEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 20:00:00 EEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom